Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 19/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL317676 | 0.83 | — | — | |
| SCHEMBL10390039 | 0.81 | GPR84 (0.62) | GPR84 | |
| Hydrochloric Acid SCHEMBL4093687 | 0.81 | GPR84 (0.49) | GPR84LOXL2 | |
| Hydrochloric Acid SCHEMBL2123585 | 0.81 | GPR84 (0.49) | GPR84LOXL2 | |
| SCHEMBL18359061 | 0.79 | GPR84 (0.56) | GPR84 | |
| SCHEMBL2867974 | 0.79 | GPR84 (0.56) | GPR84 | |
| SCHEMBL9218264 | 0.78 | GPR84 (0.74) | GPR84HTR2A | |
| SCHEMBL12592962 | 0.77 | TAAR1 (0.50) | CYP2A6HTR2ASMN1; SMN2TAAR1LOXL2 | |
| SCHEMBL9623730 | 0.76 | GPR84 (0.67) | GPR84 | |
| SCHEMBL9321427 | 0.76 | GPR84 (0.62) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621899-B1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2015-10-21 | — | — | EP | disclosed |
| US-8822463-B2 | Methylcyclohexane derivatives and uses thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2014-09-02 | — | — | US | disclosed |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| EP-2621899-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012044046-A2 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-04-05 | — | — | WO | disclosed |
| US-7956060-B2 | Pyrimidine derivative compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2011-06-07 | — | — | US | disclosed |
| US-20090012060-A1 | Antitumor Agent | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-01-08 | — | — | US | disclosed |
| EP-1749827-A1 | ANTI-TUMOR AGENT | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2007-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012060-A1 | Antitumor Agent | NR1H3, NR1I3, NR0B1 | GPR84 259/4885CYP2A6 1685/4885HTR2A 2628/4885 |
| US-20130217686-A1 | NOVEL METHYLCYCLOHEXANE DERIVATIVES AND USES THEREOF | OPRK1, OPRM1, OPRL1 | GPR84 517/4885CYP2A6 905/4885HTR2A 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.